HopeStage
Back to all studies
CompletedNCT03508700

Long-Term Safety of TNX-102 SL for People With PTSD

About this titleRead the official source — NCT03508700
Medication studyAges 18–75United States
The study in practice

Understand this study

Who was this study for?

This study was for people with PTSD. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.

Listed locations
Little Rock and 15 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: April 19, 2018
Recruitment status
Completed
Enrollment listed in the registry
93
Sponsor
Tonix Pharmaceuticals, Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 75 Years
Official registry ID
NCT03508700
Official title
Show the full official title

A 40-week Open-Label Extension Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Little Rock · Beverly Hills · Oceanside

13 more locations
  • Orange
  • Temecula
  • Colorado Springs
  • Norwich
  • Tampa
  • Atlanta
  • New Bedford
  • Las Vegas
  • Cedarhurst
  • New York
  • Canton
  • Cincinnati
  • Oklahoma City

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Tonix Pharmaceuticals, Inc.

Did this study involve medication?

Yes. The study involved medication, including TNX-102 SL 5.6 mg.

Who was this study for?

This study was for people with PTSD. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies